Hospital
Christus Spohn Health System Corporation
Christus Spohn Health System Corporation was paid $6.22M by Medicaid between Oct 2019 and Nov 2024, across 62 billing codes. Its largest line is 99284, emergency room visit (serious) — 45% of everything it billed.
33Billing provider infoCHRISTUS SPOHN HEALTH SYSTEM CORPORATION
BEEVILLE, TX 78102
BEEVILLE, TX 78102
33aNPI1447228747assigned 03/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.22M
24GClaims80,471
24DCodes billed62
24AFirst – last monthOct 2019 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#29 of 109
Median peer was paid$1.15M
This provider vs. median5.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 42 | $0.00 | |
| 2020 | 1,033 | $85K | |
| 2021 | 21,552 | $1.27M | |
| 2022 | 25,833 | $1.71M | |
| 2023 | 25,725 | $2.35M | |
| 2024incomplete | 6,286 | $798K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 45% | 4,351 | 4,120 | $2.78M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 9,950 | 9,611 | $1.93M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.1% | 5,467 | 5,313 | $253K |
| 71045 | Radiologic examination, chest; single view | 3.9% | 2,417 | 2,306 | $245K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.5% | 9,037 | 4,634 | $220K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 939 | 917 | $122K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 5,056 | 4,851 | $121K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.4% | 3,762 | 3,659 | $88K |
| 80053 | Comprehensive metabolic panel | 1.2% | 6,031 | 5,601 | $77K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,138 | 5,635 | $53K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 579 | 571 | $51K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 115 | 109 | $47K |
50 more codes
| 87070 | <1% | 3,144 | $40K | |
| 87428 | <1% | 329 | $32K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 203 | $19K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 233 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 900 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 537 | $15K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 606 | $13K |
| 81001 | <1% | 2,553 | $11K | |
| 83655 | <1% | 589 | $11K | |
| 87420 | <1% | 484 | $10K | |
| 80050 | General health panel | <1% | 52 | $9K |
| 86328 | <1% | 181 | $8K | |
| 83690 | <1% | 819 | $6K | |
| 74018 | <1% | 27 | $3K | |
| 81003 | <1% | 955 | $3K | |
| 85018 | <1% | 587 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 94 | $2K |
| 80061 | Lipid panel | <1% | 154 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 321 | $2K |
| 86140 | <1% | 97 | $1K | |
| 87081 | <1% | 156 | $1K | |
| 83605 | <1% | 202 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 91 | $1K |
| 84484 | <1% | 513 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 566 | $1K |
| 84703 | <1% | 100 | $1K | |
| 84439 | <1% | 81 | $978.39 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 908 | $917.44 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 158 | $714.76 |
| 81025 | <1% | 58 | $635.18 | |
| 83735 | <1% | 113 | $627.41 | |
| 82550 | <1% | 45 | $602.98 | |
| 84145 | <1% | 12 | $540.61 | |
| 85610 | <1% | 305 | $420.37 | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $406.57 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 143 | $348.86 |
| 85730 | <1% | 220 | $317.42 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 757 | $286.18 |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,340 | $244.88 |
| 83880 | <1% | 59 | $225.40 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 37 | $169.34 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 112 | $151.42 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 110 | $137.74 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 53 | $105.85 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 72 | $72.58 |
| 87040 | <1% | 22 | $56.55 | |
| A9270 | Non-covered item or service | 0% | 443 | $0.00 |
| 82962 | 0% | 52 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 12 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBLOW, OSBERT (CEO)
| Provider | Location | Paid |
|---|---|---|
| Christus Spohn Health System Corporation | Corpus Christi, TX | $17.62M |
| Christus Spohn Health System Corporation | Alice, TX | $10.46M |
| Christus Spohn Health System Corporation | Kingsville, TX | $5.93M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.